CELC Stock Overview
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Celcuity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.65 |
| 52 Week High | US$20.15 |
| 52 Week Low | US$7.70 |
| Beta | 0.43 |
| 1 Month Change | -18.70% |
| 3 Month Change | -34.91% |
| 1 Year Change | -55.87% |
| 3 Year Change | 15.03% |
| 5 Year Change | 59.59% |
| Change since IPO | -39.47% |
Recent News & Updates
Recent updates
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Nov 06Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Aug 31
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Jul 05Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?
May 08Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Jul 04Is Celcuity (NASDAQ:CELC) A Risky Investment?
Sep 13Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Jul 18Is Celcuity (NASDAQ:CELC) A Risky Investment?
Jan 27Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?
Sep 21Celcuity: Nipping The Oncogenic Bud
Jul 08What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition
Mar 14We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely
Jan 20Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies
Dec 23Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?
Nov 29Celcuity EPS beats by $0.03
Nov 09Shareholder Returns
| CELC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.4% | -9.9% | -9.4% |
| 1Y | -55.9% | -14.6% | -3.4% |
Return vs Industry: CELC underperformed the US Biotechs industry which returned -14.6% over the past year.
Return vs Market: CELC underperformed the US Market which returned -3.4% over the past year.
Price Volatility
| CELC volatility | |
|---|---|
| CELC Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: CELC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CELC's weekly volatility (10%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 87 | Brian Sullivan | www.celcuity.com |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform.
Celcuity Inc. Fundamentals Summary
| CELC fundamental statistics | |
|---|---|
| Market cap | US$327.31m |
| Earnings (TTM) | -US$111.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs CELC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$111.78m |
| Earnings | -US$111.78m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 84.5% |
How did CELC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/07 13:33 |
| End of Day Share Price | 2025/04/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celcuity Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |